Literature DB >> 33869801

Coexistence of osteoporosis, sarcopenia and obesity in community-dwelling adults - The Yishun Study.

Benedict Wei Jun Pang1, Shiou-Liang Wee1,2, Kenneth Kexun Chen1, Lay Khoon Lau1, Khalid Abdul Jabbar1, Wei Ting Seah1, Daniella Hui Min Ng1, Queenie Lin Ling Tan1, Mallya Ullal Jagadish1,3, Tze Pin Ng1,4.   

Abstract

OBJECTIVES: To 1) report prevalence of 'osteosarcopenia' (OS) and osteosarcopenic obesity (OSO) entities using evidence-based diagnostic techniques and definitions, 2) examine if OSO offers additional predictive value of functional decline over its components, and 3) identify associated factors in a multi-racial Southeast Asian population.
METHODS: We performed a cross-sectional study of a representative sample of 542 community-dwelling adults (21-90 years old), and assessed anthropometry, cognition, functional performance, and self-report sociodemographic, health and lifestyle questionnaires. Low muscle mass, and the Asian Working Group for Sarcopenia (AWGS) 2019 criteria, were used to assess sarcopenia. Obesity was defined using percentage body fat and fat mass index. Osteopenia/osteoporosis was determined using lumbar spinal bone mineral density. Associated factors were examined using logistic regression, and OSO's value investigated using linear regressions with functional performance.
RESULTS: OS and OSO prevalence were 1.8% and 0% (21-59 years), 12.9% and 2.8% (≥ 60 years), 17.3% and 4.1% (≥ 65 years), and 25.5% and 7.0% (≥75 years), respectively. OSO entity as defined was not a significant predictor (P > 0.05) and did not improve explanations for functional decline over sarcopenia or sarcopenic obesity. Age, sex, race and body mass index (BMI) were associated with OS, while age, sex, race and alcoholism were associated with OSO.
CONCLUSIONS: Our results do not support OSO as a distinct entity in relation to functional decline. Aside from biological age, sex, and race, amenable lifestyle factors such as BMI and alcohol intake are important variables that can influence the co-existence of osteopenia/osteoporosis, sarcopenia and obesity.
© 2020 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.

Entities:  

Keywords:  Obesity; Osteopenia; Osteosarcopenic obesity; Prevalence; Sarcopenia

Year:  2021        PMID: 33869801      PMCID: PMC8044590          DOI: 10.1016/j.afos.2020.12.002

Source DB:  PubMed          Journal:  Osteoporos Sarcopenia        ISSN: 2405-5255


Introduction

With older persons (≥ 65 years old) set to grow two-fold to 1.5 billion within the next 3 decades [1], many societies will need to better manage and delay conditions related to physiological ageing. The loss of muscle mass, strength and function with age (sarcopenia) [2], disproportionate accrual of body fat (obesity) [3], and decline in bone density and bone health (osteopenia/osteoporosis) [4] commonly accompany normal ageing. Due to their shared pathophysiological risk factors, these conditions are often found to be overlapping and mutually-aggravating. A concurrent occurrence of sarcopenia and obesity is characterized as ‘sarcopenic obesity’ (SO) [3], sarcopenia and osteopenia/osteoporosis known as ‘osteosarcopenia’ (OS) [5] while coexistence of all 3 conditions has been referred to as ‘osteosarcopenic obesity’ (OSO) [6]. The heterogeneity of diagnostic techniques and operational definitions in one or more of these components has resulted in problematic and wide-ranging reported prevalences of OS (4.7–40%) [7,8] and OSO (0.4–38%) [9,10]. Although the clinical cut-offs for osteopenia and osteoporosis have been standardized as T-scores of −1 and −2.5 for bone mineral density (BMD), respectively, measurements are often done at different regions (ie, lumbar spine, total hip or femoral neck) [4]. The identification of sarcopenia has been progressively unified by consensus working groups [2], but researchers are still divided on whether to use the full diagnostic algorithm (ie, muscle mass, strength and function) [10,11] or focus solely on a low muscle mass criterion [9] for defining sarcopenia. Perhaps the most polarized of the 3 components, obesity currently has no unified or universally-accepted definition. Body mass index (BMI), waist circumference (WC), percentage body fat (PBF), fat mass index (FMI) and fat mass to fat-free mass ratio (FM/FFM) are just some of the more commonly used measures, each assessing a distinct concept of obesity [12]. To better comprehend its fundamental pathophysiology, estimate its prevalence and explore possible treatments, it is important to advance towards an integrated criteria for the identification and characterisation of OSO. In recent years, OSO has been proposed as a cumulative triad of the adverse effects of its components: impaired bone health, muscle health, and excess adiposity [6]. We have recently reported population prevalence of osteopenia, osteoporosis [13], sarcopenia [14], obesity and SO [15], and provided reference values for BMD [13], skeletal muscle, strength and function [14], and compared different adiposity measures [15]. Additionally, we have also shown that SO further exacerbates poor physical function when compared to sarcopenia or obesity alone [15]. However, there is contrasting evidence regarding the value of OSO in predicting for functional decline (ie, physical performance and frailty) [5,16], risk of adverse clinical outcomes (ie, fractures and falls risks) [17,18] and mortality [19] over sarcopenia, osteopenia/osteoporosis, or SO alone. Therefore, more studies on the characteristics and value of OSO are needed [6]. The main objective of this cross-sectional study is to report OS and OSO prevalence using evidence-based diagnostic techniques and definitions. We further examined if OSO offers additional predictive value of functional decline over sarcopenia and sarcopenic obesity, and identified the risk factors for OS and OSO in a multi-racial Southeast Asian population of community-dwelling adults.

Methods

Setting

Community-dwellers (≥ 21 years old) were recruited from Yishun, one of the largest north-residential towns in Singapore. It has a resident population of 220,320 (50.6% females), 12.2% of which are older than 65 years, comparable to the general Singapore population of 4,026,210 (51.1% females), 14.4% of which older than 65 years [20].

Participants

A representative sample of around 300 men and 300 women was recruited through random sampling, with 20–40 in each age- and sex-group (10-year intervals for 21–60 years; 5-year intervals for ≥ 60 years). Detailed recruitment methods and exclusion criteria have been reported previously [14]. Research ethics were approved by the National Healthcare Group DSRB (2017/00212). All participants undertook informed consent prior to study recruitment.

Questionnaires

Self-report questionnaires were administered, relating to education, accommodation, living arrangement, marital status, tobacco and alcohol use, history of disease and conditions, mini nutritional assessment (MNA) short form [21], and the global physical activity questionnaire (GPAQ) [22] and Longitudinal Aging Study Amsterdam (LASA) physical activity questionnaires [23].

Anthropometry

Height (m) and weight (kg) were assessed with a digital balance and stadiometer (Seca, GmbH & Co. KG, Hamburg, Germany). Waist and hip circumferences were determined with a tape measure encircling the narrowest waist and widest hip regions accordingly. Body mass index (BMI) was computed as weight over height squared (kg/m2).

Cognition

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) was administered to evaluate cognitive functions including memory, visuospatial, language and attentional domains, totalling to 0–321 points [24]. Higher points indicate greater global cognition.

Functional performance

To assess functional deterioration or limitation, participants performed the short physical performance battery (SPPB). The SPPB is an objective and validated assessment comprising the components of balance, gait speed, and sit-to-stands [25].

Sarcopenia, obesity and osteopenia/osteoporosis

Sarcopenia was assessed and defined in 2 ways: the Asian Working Group for Sarcopenia criteria (AWGS 2019; ie, AWGS-based) [2], and according to poor skeletal muscle alone, ie, appendicular lean mass index (ALMI-based). ALMI, muscle strength and physical function were measured using a dual-energy X-ray absorptiometry (DXA) scan, maximal handgrip strength and habitual gait speed tests respectively, with detailed methods described in an earlier paper [14]. Obesity was assessed using the DXA scan, and defined using the 2 upper quintiles of population-derived sex-specific percentage body fat (PBF) and fat mass index (FMI) values [15]. We have previously shown that FMI is the more favourable approach for assessing adiposity as a component of sarcopenic obesity [15]. Osteopenia and osteoporosis were indicated by a population-derived lumbar spinal bone mineral density (BMDLS) T-score of −1 to −2.5 and ≤ −2.5 respectively [4]. Detailed methods, along with osteopenia/osteoporosis prevalence and reference values, have been described elsewhere [13].

Osteosarcopenia and osteosarcopenic obesity

Participants who were sarcopenic and osteopenic/osteoporotic only were classified as ‘osteosarcopenic’ (OS), while those who were osteosarcopenic and obese were classified as ‘osteosarcopenic obese’ (OSO).

Statistical analysis

Data analysis was done using SPSS version 22 (Chicago, Illinois, USA). Continuous and categorical variables were presented as mean (SD) and number (%) respectively. Prevalence approximations of OS and OSO were adjusted to the overall Singapore population by age-group weights. Multiple linear regressions were performed against SPPB to compare the effects of the respective phenotypes on physical function. Backward stepwise logistic regressions (removal threshold: P = 0.05) were employed to identify variables correlated with OS and OSO, with no correction for multiple significance testing (significance level: P < 0.05).

Results

Among the 542 participants recruited (21–90 years old; 57.9% females), n = 6 and n = 1 had inadequate sarcopenia and obesity data respectively, while n = 72 were excluded due to poor DXA scan imaging (ie, body portions cut-off, or participants with considerably large metal implants including hip/knee replacements). Therefore, data analysis was performed for the remaining 463 participants, aged 57.9 (18.5) years on average, 82.1% of which were Chinese, 8.6% Malay, 6.5% Indians, and 2.8% of other races. ‘Race’ was defined as Chinese, Malay, Indian, or others by biological origin (ie, skin color), rather than by social, national or cultural contexts.

Prevalence

Population-adjusted prevalence of AWGS-based OS was 4.7%, OSO–PBF 2.1%, and OSO-FMI 0.7% (Table 1). For the ALMI-based definitions, overall population-adjusted prevalence of OS was 14.5%, OSO–PBF 3.9%, and OSO-FMI 1.9%. The trendlines of OS and OSO with age are displayed in Fig. 1, Fig. 2. Descriptive statistics and corresponding OSO categories are presented in Table 2.
Table 1

Prevalence estimates adjusted to the Singapore general population by age group weights.

VariableALMI-based
AWGS-based
OSOSO–PBFOSO-FMIOSOSO–PBFOSO-FMI
Total Residents14.53.91.94.72.10.7
 21–59 Years9.82.20.61.81.00.0
 ≥ 60 Years27.88.75.312.95.32.8
 ≥ 65 Years32.210.26.217.37.94.1
 ≥ 75 Years34.211.08.725.58.67.0



Total Male Residents10.32.92.31.70.90.4
 21–59 Years6.51.31.30.00.00.0
 ≥ 60 Years21.17.65.36.73.51.6
 ≥ 65 Years22.87.84.38.35.32.4
 ≥ 75 Years24.95.84.113.14.14.1



Total Female Residents18.54.91.57.63.31.0
 21–59 Years12.93.10.03.62.00.0
 ≥ 60 Years34.09.75.418.66.93.9
 ≥ 65 Years40.512.47.925.310.25.7
 ≥ 75 Years41.515.212.335.312.19.2

ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; OS, osteosarcopenia; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index.

Values are presented as percentages (%).

Fig. 1

Age-trends of ALMI-based osteosarcopenia and osteosarcopenic obesity prevalence.

y: years, OS: osteosarcopenia, OSO: osteosarcopenic obesity, ALMI: appendicular lean mass index, AWGS: Asian Working Group for Sarcopenia, PBF: percentage body fat, FMI: fat mass index, N: sample size.

Fig. 2

Age-trends of AWGS-based osteosarcopenia and osteosarcopenic obesity prevalence.

y: years, OS: osteosarcopenia, OSO: osteosarcopenic obesity, ALMI: appendicular lean mass index, AWGS: Asian Working Group for Sarcopenia, PBF: percentage body fat, FMI: fat mass index, N: sample size.

Table 2

Participant characteristics and osteosarcopenic obesity statuses.

CharacteristicsTotal n = 463ALMI-based
AWGS-based
OSO–PBF n = 31OSO-FMI n = 18OSO–PBF n = 20OSO-FMI n = 11
Age, yr
 21-40106 (22.9)0 (0.0)0 (0.0)0 (0.0)0 (0.0)
 41-60103 (22.2)6 (19.4)2 (11.1)2 (10.0)0 (0.0)
 61-80211 (45.6)19 (61.3)11 (61.1)13 (65.0)7 (63.6)
 ≥ 8143 (9.3)6 (19.4)5 (27.8)5 (25.0)4 (36.4)
Sex
 Male204 (44.1)10 (32.3)7 (38.9)5 (25.0)3 (27.3)
 Female259 (55.9)21 (67.7)11 (61.1)15 (75.0)8 (72.7)
Race
 Chinese380 (82.1)24 (77.4)13 (72.2)15 (75.0)7 (63.6)
 Malay40 (8.6)1 (3.2)1 (5.6)1 (5.0)1 (9.1)
 Indian30 (6.5)5 (16.1)3 (16.7)3 (15.0)2 (18.2)
 Others13 (2.8)1 (3.2)1 (5.6)1 (5.0)1 (9.1)
Highest Qualification
 ≤ Primary141 (30.5)12 (38.7)7 (38.9)10 (50.0)5 (45.5)
 Secondary147 (31.7)11 (35.5)5 (27.8)8 (40.0)5 (45.5)
 Tertiary100 (21.6)5 (16.1)4 (22.2)2 (10.0)1 (9.1)
 ≥ Degree75 (16.2)3 (9.7)2 (11.1)0 (0.0)0 (0.0)
Housing Type
 1–2 rooms56 (12.1)4 (12.9)2 (11.1)3 (15.0)1 (9.1)
 3 rooms97 (21.0)10 (32.3)4 (22.2)8 (40.0)4 (36.4)
 4–5 rooms270 (58.3)14 (45.2)9 (50.0)7 (35.0)4 (36.4)
 High-end Public/Private40 (8.6)3 (9.7)3 (16.7)2 (10.0)2 (18.2)
Living Arrangement (n = 421)
 Alone36 (8.6)5 (16.7)3 (16.7)4 (20.0)2 (18.2)
 Not Alone385 (91.4)25 (83.3)15 (83.3)16 (80.0)9 (81.8)
Marital Status (n = 440)
 Married307 (69.8)21 (67.7)12 (66.7)12 (60.0)6 (54.5)
 Single71 (16.1)1 (3.2)0 (0.0)0 (0.0)0 (0.0)
 Divorced/Separated15 (3.4)1 (3.2)1 (5.6)0 (0.0)0 (0.0)
 Widowed47 (10.7)8 (25.8)5 (27.8)8 (40.0)5 (45.5)
Medical Conditions
 Diabetes66 (14.3)4 (12.9)3 (16.7)3 (15.0)2 (18.2)
 Hypertension161 (34.8)16 (51.6)12 (66.7)13 (65.0)9 (81.8)
 High Cholesterol175 (37.8)18 (58.1)12 (66.7)13 (65.0)8 (72.7)
Smoking and Drinking
 Smokers/Ex-smokers102 (22.0)6 (19.4)4 (22.2)4 (20.0)3 (27.3)
 Alcoholics/Ex-alcoholics38 (8.2)4 (12.9)3 (16.7)3 (15.0)3 (27.3)
 Smoke and Drink21 (4.5)1 (3.2)1 (5.6)1 (5.0)1 (9.1)

ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index.

Values are presented as mean (SD) or number (%).

Prevalence estimates adjusted to the Singapore general population by age group weights. ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; OS, osteosarcopenia; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index. Values are presented as percentages (%). Age-trends of ALMI-based osteosarcopenia and osteosarcopenic obesity prevalence. y: years, OS: osteosarcopenia, OSO: osteosarcopenic obesity, ALMI: appendicular lean mass index, AWGS: Asian Working Group for Sarcopenia, PBF: percentage body fat, FMI: fat mass index, N: sample size. Age-trends of AWGS-based osteosarcopenia and osteosarcopenic obesity prevalence. y: years, OS: osteosarcopenia, OSO: osteosarcopenic obesity, ALMI: appendicular lean mass index, AWGS: Asian Working Group for Sarcopenia, PBF: percentage body fat, FMI: fat mass index, N: sample size. Participant characteristics and osteosarcopenic obesity statuses. ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index. Values are presented as mean (SD) or number (%). Across age groups, AWGS-based OS prevalence were 1.8% (21–59 years), 12.9% (≥ 60 years), 17.3% (≥ 65 years) and 25.5% (≥ 75 years); OSO–PBF prevalence were 1.0%, 5.3%, 7.9% and 8.6%; and OSO-FMI prevalence were 0%, 2.8%, 4.1% and 7.0%, respectively. For the ALMI-based definitions, OS prevalence were 9.8% (21–59 years), 27.8% (≥60 years), 32.2% (≥65 years) and 34.2% (≥75 years); OSO–PBF prevalence were 2.2%, 8.7%, 10.2% and 11.0%; and OSO-FMI prevalence were 0.6%, 5.3%, 6.2% and 8.7%, respectively.

Multiple linear regression

In multiple linear regression analyses of the respective conditions for SPPB (dependent variable), we adjusted for age, sex, race, education, accommodation, living arrangement, marriage status, diabetes, hypertension, high cholesterol, self-rated health, smoking, alcoholism, MNA, GPAQ, LASA, BMI, waist and hip circumferences, and RBANS (independent variables; Table 3). Across all models, the OSO phenotypes did not explain for any increase in variance (R2 = 0.206–0.209) of SPPB functional performance over the sarcopenic (R2 = 0.206–0.211) and sarcopenic obese (R2 = 0.209–0.221) phenotypes. Ordinal logistic regressions were additionally performed across all 6 models for SPPB to confirm our findings that the OSO phenotypes did not increase the predictive value of the models on functional performance (estimated Cox and Snell, Nagelkerke, and McFadden R2 values) compared to the sarcopenic and sarcopenic obese phenotypes. None of the models violated the assumption of multicollinearity.
Table 3

Multiple linear regression analysis for SPPB.

ALMI-based
AWGS-based
ModelAdjusted R2βP-valueModelAdjusted R2βP-value
S0.2060.0150.807S0.211−0.0810.130
SO–PBF0.209−0.0560.250SO–PBF0.214−0.0950.049∗
SO-FMI0.209−0.0600.211SO-FMI0.221−0.1310.006∗∗
OSO–PBF0.206−0.0110.813OSO–PBF0.207−0.0310.492
OSO-FMI0.207−0.0240.596OSO-FMI0.209−0.0550.230

SPPB, short physical performance battery; ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; β, standardized coefficient; S, sarcopenia; SO, sarcopenia obesity; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index.

∗ denotes P < 0.05; ∗∗ denotes P < 0.01; ∗∗∗ denotes P < 0.001.

Model includes Age, Sex, Race, Education Level, Housing Type, Living Arrangement, Marital Status, Diabetes, Hypertension, High Cholesterol, Self-rated Health, Smoking, Alcoholism, Mini Nutritional Assessment, Global Physical Activity Questionnaire, Longitudinal Aging Study Amsterdam Physical Activity Questionnaire, Body Mass Index, Waist Circumference, Hip Circumference, and Repeatable Battery for the Assessment of Neuropsychological Status.

Multiple linear regression analysis for SPPB. SPPB, short physical performance battery; ALMI, appendicular lean mass index; AWGS, Asian Working Group for Sarcopenia; β, standardized coefficient; S, sarcopenia; SO, sarcopenia obesity; OSO, osteosarcopenic obesity; PBF, percentage body fat; FMI, fat mass index. ∗ denotes P < 0.05; ∗∗ denotes P < 0.01; ∗∗∗ denotes P < 0.001. Model includes Age, Sex, Race, Education Level, Housing Type, Living Arrangement, Marital Status, Diabetes, Hypertension, High Cholesterol, Self-rated Health, Smoking, Alcoholism, Mini Nutritional Assessment, Global Physical Activity Questionnaire, Longitudinal Aging Study Amsterdam Physical Activity Questionnaire, Body Mass Index, Waist Circumference, Hip Circumference, and Repeatable Battery for the Assessment of Neuropsychological Status.

Associated factors

Variables associated with AWGS-based OS and OSO are shown in Table 4. Increasing age, female sex, non-Chinese race and lower BMI were risk factors of OS (P < 0.01), while increasing age, female sex, non-Chinese race and alcoholism (P < 0.05) were risk factors of OSO. For OS, the regression model explained for 37.7% (Nagelkerke R) of the variance and correctly classified 90.5% of the cases, while for OSO-FMI, the model explained for 32.6% of the variance and correctly classified 97.4% of the cases. Multicollinearity was not violated in any of the models.
Table 4

Factors associated with AWGS-based OS and OSO using logistic regression.

CharacteristicsOS
OSO-FMI
OSO–PBF
R2Percentage Correct (%)Odds Ratio (95% CI)R2Percentage Correct (%)Odds Ratio (95% CI)R2Percentage Correct (%)Odds Ratio (95% CI)
37.790.532.697.416.795.2
Age, yr1.11 (1.07–1.15)∗∗∗1.16 (1.06–1.26)∗∗1.08 (1.03–1.13)∗∗
Sex
 Female111
 Male0.20 (0.09–0.47)∗∗∗0.17 (0.03–0.94)∗0.32 (0.11–0.91)∗
Race
 Non-Chinese11
 Chinese0.24 (0.09–0.66)∗∗0.17 (0.04–0.72)∗
Alcoholism
 No1
 Yes9.88 (1.76–55.58)∗∗
BMI, kg/m20.74 (0.65–0.84)∗∗∗

AWGS, Asian Working Group for Sarcopenia; OS, osteosarcopenia; OSO, osteosarcopenic obesity; FMI, fat mass index; PBF, percentage body fat; BMI, body mass index.

∗ denotes P < 0.05; ∗∗ denotes P < 0.01; ∗∗∗ denotes P < 0.001.

Factors associated with AWGS-based OS and OSO using logistic regression. AWGS, Asian Working Group for Sarcopenia; OS, osteosarcopenia; OSO, osteosarcopenic obesity; FMI, fat mass index; PBF, percentage body fat; BMI, body mass index. ∗ denotes P < 0.05; ∗∗ denotes P < 0.01; ∗∗∗ denotes P < 0.001.

Discussion

As the first population-based study to present ‘osteosarcopenia’ (OS) and ‘osteosarcopenic obesity’ (OSO) prevalence among younger (21–59 years) and older (≥ 60 years) community-dwellers in a multi-racial, Southeast Asian population, our findings contribute important information to the knowledge base on OS and OSO entities. It should be noted that while OS and OSO are conditions relating to older people, we applied the same criteria in younger adults in order to estimate prevalence across adult age groups, and so this would have likely been an underestimate for the younger adults. In a similar study done on community-dwelling Korean adults (≥ 50 years) [9], the overall prevalence of OSO based on low bone mineral density (BMD), high percentage body fat (PBF) and low skeletal muscle was 6.6%. Similarly, among our representative sample of Singaporean adults (≥ 50 years), OSO prevalence as defined by the same diagnostic methods was comparable at 7.1%. In another study on Japanese men and women (≥40 years) [11], the overall OSO prevalence among the community-dwellers based on low BMD, high PBF and sarcopenia based on the 2014 Asian Working Group for Sarcopenia criteria (AWGS 2014) [26] was 0.9%. This was lower compared to the prevalence of 3.3% among our representative Singaporean sample (≥40 years). However, it should be noted that the AWGS 2014 criteria used in the Japanese study has lower cut-off values for muscle strength and function as compared to the updated AWGS 2019 criteria [2] used in our study, thus leading to a lower prevalence of sarcopenia and OSO. We have recently shown that by using the AWGS 2019 versus the AWGS 2014 criteria, sarcopenia prevalence alone was inflated by more than two-fold [14].

No evidence of osteosarcopenic obesity as a distinct entity

Multiple linear regression analyses of SPPB showed that, across all models, functional deterioration was not more severe in individuals with OSO compared to those from the sarcopenic-only or sarcopenic obese groups. A recent critical literature review [6] highlighted the concerns regarding the utility of OSO as a distinct entity, and questioned its value in predicting increased risks of adverse outcomes over and above that of its constituents. Osteopenia/osteoporosis did not elevate falls and frailty risks any more than sarcopenia [16,18,27]. Additionally, although some researchers have shown significant correlation between OSO and poor functional performance when compared to non-OSO individuals [11,28], our findings revealed that this association with decreased function is attributable to the sarcopenia and obesity components of OSO. OSO itself, or the addition of osteopenia/osteoporosis to sarcopenic obesity, did not correlate with functional performance. Therefore, our results do not support OSO as a discrete entity in relation to physical function. Nevertheless, the concurrence of osteopenia/osteoporosis, sarcopenia and/or obesity among community-dwelling adults still presents a noteworthy public health concern. To further determine the importance of OSO, future studies should evaluate the severity of other adverse clinical outcomes that are associated with OSO (ie, fractures [17,27] disability [29], hospitalization [28], and mortality [19]) in comparison to that of its components alone. Backward stepwise logistic regression, for AWGS-based definitions, identified increasing age, female sex, non-Chinese race and lower BMI as risk factors for OS. Furthermore, increasing age, female sex, non-Chinese race as well as alcoholism were risk factors for OSO. In sensitivity analyses, forward stepwise and full saturated logistic regression models identified the same variables for OS. With OSO, forward stepwise model found one less variable (ie, sex), while the full saturated model found one different variable (ie, self-rated health instead of alcoholism) than the backward model. One shortcoming of the forward selection is “suppressor effects”, while allowing evidently insignificant variables to remain as with the saturated model can influence the significance of other variables. Not surprisingly, increasing age and the female sex elevated the risks of OS and OSO. Due to the effects of progressive physiological decline, deterioration in bone mass, bone health, muscle mass, strength, function, and increase in fat mass, are natural occurrences even with ‘normal aging’ [6]. Additionally, women at all ages inherently have much higher relative fat mass [30] and much lower skeletal muscle and bone mass [30] compared with men, attributed mainly to disparities in hormonal profiles. Elevated testosterone in men promotes bone and muscle anabolism [31], while women have inflated estrogen that encourages fat storage around the chest, hips and thighs [32]. Non-Chinese races had an increased risk of OS and OSO compared to the Chinese, even after adjusting for all available sociodemographic, lifestyle, and medical factors. Observations of racial differences arising from genetic predispositions can be abstruse and difficult to explain. A study on quality of life among Singaporean adolescents reported significant racial differences regardless of health and socioeconomic profiles, indicating key differences among the different races [33]. Chinese Singaporeans also had the lowest BMI, lowest HbA1c levels, and were least likely to have diabetes compared to their Malay and Indian counterparts – even after adjusting for factors like age, sex and exercise [34]. Other studies have reported that Chinese Singaporeans were least likely to suffer a myocardial infarction, or to die from one, compared to Malays and Indians, attributable to unfavourable racial predispositions that cannot be fully explained by dietary intake [35]. In addition, Malays and Indians were more than twice as likely as Chinese to develop dementia, even with adjustments for age, sex and education, suggesting fundamental variations in heredity among the different races [36]. Racial predispositions have sometimes been attributed to modifiable lifestyle factors (ie, physical activity, diet, and obesity). Particularly, significant associations were reported previously between diet quality and OSO [37,38]. Malay Singaporeans are known to consume the largest amounts of saturated and total fat, and fewest servings of vegetables and fruits [39], modifiable lifestyle factors that translated to significantly lower life expectancies compared to the Chinese and Indians [40]. According to FMI and PBF definitions, our findings showed that 60.2% and 55.4% of non-Chinese were obese, almost double that of the Chinese at 33.2% and 34.7% respectively. Obesity alone is associated with functional decline [41], morbidity [42], and metabolic syndrome [43], and its pro-inflammatory effects are known to perpetuate insulin resistance and contribute to a decline in muscle and bone health [3]. Furthermore, obesity is associated with lower activity levels, further exacerbating the reduction in bone mass, muscle mass, and strength [30]. Although activity levels and nutritional status, measured by GPAQ and MNA short form, were not found to be significant predictors of OS and OSO, GPAQ quantifies activity by MET hours (ie, calories burned per kg of body weight), and does not account for exercise intensity (higher intensity preserves muscle mass and strength) or impact (greater impact preserves bone density) [22]. Additionally, MNA short form does not assess nutritional intake – such as protein (to preserve muscle) and calcium or vitamin D (for bone health) [21]. Therefore, more specific measures of physical activity and dietary intake could exemplify our understanding of the effects of modifiable lifestyle factors on OS and OSO. Alcoholism was associated with OSO. Alcohol consumption in excess perpetuates systemic inflammation, resulting in adverse health outcomes including movement inhibition and diminished functional efficiency [44]. Interestingly, lower BMI increased the risk of OS but not OSO. Higher BMI is an indicator of better nourishment, where greater protein, nutrient and caloric intake translate to improved muscle and bone health compared with the undernourished [30,45]. Since BMI is a direct indicator of obesity, the effects of lower BMI on elevated disease risk disappeared in the OSO model. The strengths of this study are its population-based nature, thoroughness of data collection and application of up-to-date and evidence-based consensus. There are also several limitations. Although race was identified as a risk factor in multivariate logistic regression, our study was not adequately powered for racial comparisons as we did not have the same proportion of participants by race (ie, Malays and Indians are under-represented in our sample). Further studies may be required to exemplify our understanding of the effects of biological race on OS and OSO risk. With a cross-sectional design, causality of disease from risk factors also cannot be inferred, and age-associated changes may not truly represent the longitudinal trajectories of bone health, muscle health and adiposity. Without BMD of the hip or femoral neck, we used only lumbar spinal BMD to determine osteopenia and osteoporosis, which could have led to an under-detection of OS and OSO. Finally, the study subjects were community-dwellers, which may implicate the generalizability of the results to the disabled, hospitalized or institutionalized.

Conclusions

This study contributes important information to improve the understanding and identification of OS and OSO among community-dwellers. We did not find evidence to bolster OSO as a distinct entity with regards to physical function. To further determine its importance, future studies should evaluate the severity of other adverse clinical outcomes associated with OSO (ie, fractures, disability, hospitalization and mortality) in comparison to that of its components alone. Apart from increasing age, female sex, and biological race, amenable lifestyle factors including BMI and alcohol intake are important variables that can influence the development of osteosarcopenia and osteosarcopenic obesity.

CRediT author statement

Benedict Wei Jun Pang: Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data curation, Writing - original draft, Writing - review & editing, Project administration. Shiou-Liang Wee: Conceptualization, Methodology, Writing - review & editing, Supervision, Project administration, Funding acquisition. Kenneth Kexun Chen: Formal analysis, Investigation, Resources, Data curation. Lay Khoon Lau: Formal analysis, Investigation, Resources, Data curation, Project administration. Khalid Abdul Jabbar: Formal analysis, Investigation, Resources, Data curation. Wei Ting Seah: Formal analysis, Investigation, Resources, Data curation. Daniella Hui Min Ng: Formal analysis, Investigation, Resources, Data curation. Queenie Lin Ling Tan: Formal analysis, Investigation, Resources, Data curation. Mallya Ullal Jagadish: Conceptualization, Methodology, Supervision. Tze Pin Ng: Conceptualization, Methodology, Supervision.

Conflicts of interest

The authors declare no competing interests.
  40 in total

1.  Risk of Nonspine Fractures in Older Adults with Sarcopenia, Low Bone Mass, or Both.

Authors:  Didier Chalhoub; Peggy M Cawthon; Kristine E Ensrud; Marcia L Stefanick; Deborah M Kado; Robert Boudreau; Susan Greenspan; Anne B Newman; Joseph Zmuda; Eric S Orwoll; Jane A Cauley
Journal:  J Am Geriatr Soc       Date:  2015-08-27       Impact factor: 5.562

2.  Correction to: Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review.

Authors:  Jürgen M Bauer; Alfonso J Cruz-Jentoft; Roger A Fielding; John A Kanis; Jean-Yves Reginster; Olivier Bruyère; Matteo Cesari; Roland Chapurlat; Nasser Al-Daghri; Elaine Dennison; Jean-Marc Kaufman; Francesco Landi; Andrea Laslop; Médéa Locquet; Stefania Maggi; Eugene McCloskey; Simone Perna; René Rizzoli; Yves Rolland; Mariangela Rondanelli; Pawel Szulc; Bruno Vellas; Mila Vlaskovska; Cyrus Cooper
Journal:  Calcif Tissue Int       Date:  2019-08       Impact factor: 4.333

3.  A cross-sectional study of loss of muscle mass corresponding to sarcopenia in healthy Chinese men and women: reference values, prevalence, and association with bone mass.

Authors:  Qun Cheng; Xiaoying Zhu; Xuemei Zhang; Huilin Li; Yanping Du; Wei Hong; Sihong Xue; Hanmin Zhu
Journal:  J Bone Miner Metab       Date:  2013-04-26       Impact factor: 2.626

4.  Diet quality and osteosarcopenic obesity in community-dwelling adults 50 years and older.

Authors:  Jinhee Kim; Yunhwan Lee; Seunghee Kye; Yoon-Sok Chung; Jae-Hyun Kim; Doukyoung Chon; Kyung Eun Lee
Journal:  Maturitas       Date:  2017-08-10       Impact factor: 4.342

5.  Obesity Definitions in Sarcopenic Obesity: Differences in Prevalence, Agreement and Association with Muscle Function.

Authors:  E Q Khor; J P Lim; L Tay; A Yeo; S Yew; Y Y Ding; W S Lim
Journal:  J Frailty Aging       Date:  2020

6.  Ethnic differences among Chinese, Malay and Indian patients with type 2 diabetes mellitus in Singapore.

Authors:  C Y Hong; K S Chia; K Hughes; S L Ling
Journal:  Singapore Med J       Date:  2004-04       Impact factor: 1.858

7.  Risk of Fracture in Women with Sarcopenia, Low Bone Mass, or Both.

Authors:  Rebekah Harris; Yuefang Chang; Kristen Beavers; Deepika Laddu-Patel; Jennifer Bea; Karen Johnson; Meryl LeBoff; Catherine Womack; Robert Wallace; Wenjun Li; Carolyn Crandall; Jane Cauley
Journal:  J Am Geriatr Soc       Date:  2017-09-27       Impact factor: 5.562

8.  Association of osteosarcopenic obesity and its components: osteoporosis, sarcopenia and obesity with insulin resistance.

Authors:  Kayoung Lee
Journal:  J Bone Miner Metab       Date:  2020-04-25       Impact factor: 2.626

Review 9.  Estrogen Deficiency and the Origin of Obesity during Menopause.

Authors:  Fernando Lizcano; Guillermo Guzmán
Journal:  Biomed Res Int       Date:  2014-03-06       Impact factor: 3.411

Review 10.  Osteosarcopenia: A case of geroscience.

Authors:  Ben Kirk; Ahmed Al Saedi; Gustavo Duque
Journal:  Aging Med (Milton)       Date:  2019-09-08
View more
  4 in total

1.  Osteosarcopenic obesity and its components-osteoporosis, sarcopenia, and obesity-are associated with blood cell count-derived inflammation indices in older Chinese people.

Authors:  Yi-Zhen Nie; Zhao-Qi Yan; Hui Yin; Ling-Han Shan; Jia-Hui Wang; Qun-Hong Wu
Journal:  BMC Geriatr       Date:  2022-06-28       Impact factor: 4.070

Review 2.  Vitamin D in Osteosarcopenic Obesity.

Authors:  Luigi Di Filippo; Rebecca De Lorenzo; Andrea Giustina; Patrizia Rovere-Querini; Caterina Conte
Journal:  Nutrients       Date:  2022-04-26       Impact factor: 6.706

3.  Comparison of Physical Function among Elderly Japanese Women with and without Low Bone Mass and Low Muscle Mass: A Cross-Sectional Study of Older Women Who Engage in Regular Physical Activity.

Authors:  Tsuyoshi Katsurasako; Shin Murata; Akio Goda; Hideki Nakano; Kayoko Shiraiwa; Jun Horie; Koji Nonaka
Journal:  Geriatrics (Basel)       Date:  2022-09-14

4.  Sarcopenic osteoporosis, sarcopenic obesity, and sarcopenic osteoporotic obesity in the Camargo cohort (Cantabria, Spain).

Authors:  Paula Hernández-Martínez; José M Olmos; Javier Llorca; José L Hernández; Jesús González-Macías
Journal:  Arch Osteoporos       Date:  2022-07-29       Impact factor: 2.879

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.